Leprosy Treatment Market 2019 Growth, Key Regions, Segments, Worldwide Players and Clinical Diagnostic Sector to Inspire Better Intake of Global Market
Key Players in the Global Leprosy Treatment Market
The leading companies operating in the global leprosy treatment market include Glaxo Smith Kline Pharmaceuticals Ltd., Systopic Laboratories Pvt. Ltd., Acme Pharmaceuticals, Cadila Pharmaceuticals, Macleods Pharmaceuticals, IDPL, Astra Zeneca Pharma India Ltd., Lark Laboratories (UIndia) Ltd., Genetic Pharma, and Novartis International AG.
Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/128
Global Leprosy Treatment Market
Leprosy, also reckoned as Hansen’s disease (HD), is a chronic infection caused by Mycobacterium lepromatosis or the Mycobacterium leprae bacteria. Leprosy is principally a granulomatous disease. The significant symptoms of leprosy include reddish skin lesions, loss of sensation, and weakness of hands and muscles. Nerve damage is the primary cause for numbness of muscles. Leprosy is a communicable disease that can be propagated through contact with cough or phlegm of the affected person. Other risk factors of leprosy include malnutrition and weak immune system. Leprosy is especially prevalent in low-income countries.
Global Leprosy Treatment Market Outlook
According to the statistics compiled by the World Health Organization (WHO), from various regions (around 138 countries), the number of registered cases of leprosy was 176,176 in 2015, that is 0.18 cases per 10 000 people. The number of new cases shows the degree of sustained transmission of the disease. Global statistics illustrate that 203,600 (96%) of fresh leprosy cases were from 22 key countries. Prevalence of high occurrences is a reminder that some areas around the world show high incidences of the disease and experience very high rate of transmission. As per the same source, around 16 million cases of leprosy have been reported over the last two decades. Several governments are trying to eradicate the prevalence of the disease on a global scale. Owing to these factors, the leprosy treatment market is expected to grow at substantial rate over the forecast period (2016–2024).
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/128
As per the National Leprosy Eradication Program (NLEP), leprosy has been broadly categorized into two segments namely, paucibacillary leprosy (one to five skin lesions, maximum one nerve with skin liaisons) and multibacillary leprosy (over six skin liaisons, more than one nerve with skin liaisons). Early detection of the disease is an important factor for effective treatment, though various drugs are available for late-stage leprosy patients. The most common treatment for leprosy is the multidrug therapy. The drugs recommended by WHO multidrug therapy are rifampicin, dapsone, and clofazimine. Among these, rifampicin is most preferred drug for the treatment of leprosy. Treatment with everyday dapsone and monthly treatment with rifampicin for six months is followed for paucibacillary (PB or tuberculoid) cases. For multibacillary (MB or lepromatous) cases, the treatment is a prolonged one. It includes daily dapsone and clofazimine. In addition, monthly rifampicin is recommended for 12 months. Side effects, resistance, and relapse rate are low in multidrug therapy. Some of the other drugs available for leprosy treatment are Rifadine and Rimactane. The leprosy treatment market is projected to witness a steep incline in the number of novel drugs and availability of the same, due to increasing initiatives across the globe to eradicate this menace.
Leprosy has been endemic to mankind since many decades. This needed interference of various governments around the world as well as the World Health Organization. Governments play an important role in the leprosy treatment market. Ever since the introduction of multidrug therapy by WHO in 1982, governments around the world have adopted this treatment procedure on a large scale. Some of them subsidized the treatment to eradicate the presence of the disease from their countries. Therefore government regulation as well as adoption remains the most important driver of the leprosy treatment market.
Global Leprosy Treatment Market – Geographical Outlook
In Asia Pacific, India remains one of the most affected countries. As per the WHO reports, about 59% of the new cases reported were from India. According to the stats released by the Leprosy Mission Trust, around 127,000 new occurrences of leprosy were reported from India alone during 2013–2014. Out of these, about 46% were women and children. In India, the prevalence rate according to The Leprosy Mission Trust in the year 2014 was about 0.68 per 10,000 population. The National Leprosy Eradication Program (NLEP) is one such initiative by the Indian government that aims to eradicate the disease from the country by 2018. Thus, the leprosy treatment market in this region is projected to grow at a considerable rate in the near future.
The key market players are focused on various business strategies, such as gaining product approval from regulatory authorizes, collaborations and partnerships, etc. in order to expand their product portfolio and gain a competitive edge in the market. For instance, in February 2019, Novartis International AG received U.S. Food and Drug Administration approval for ‘Egaten’, a drug used for fascioliasis and tropical diseases, which include leprosy. In March 2019, The Novartis Foundation, a non-profit organization and part of Novartis International AG, signed a partnership deal with Microsoft to develop artificial intelligence (AI)-enabled digital health tool and a leprosy intelligent image atlas to boost the early detection of leprosy. Furthermore, HDT Biotech Corporation collaborated with Infectious Disease Research Institute (IDRI) in September 2018, to develop a cost-effective test with enhanced sensitivity for detecting infection with M. leprae, which causes leprosy.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/leprosy-treatment-market-128
Global Leprosy Treatment Market Taxonomy
Based on the type of leprosy, the global leprosy treatment market is segmented into:
- Early and indeterminate leprosy treatment
- Borderline tuberculoid leprosy treatment
- Tuberculoid leprosy treatment
- Borderline leprosy treatment
- Histoid leprosy treatment
- Lepromatous leprosy treatment
- Borderline lepromatous leprosy treatment
- Diffuse leprosy of Lucio and Latapí
Based on treatment type, the global leprosy treatment market is classified as:
- Multidrug Therapy
The global leprosy treatment market comprises a number of end-users, including:
- Medical Practitioners
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire